Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Delayed Nogo receptor therapy improves recovery from spinal cord contusion.

Annals of neurology | Nov 6, 2006

OBJECTIVE: Myelin-associated inhibitors play a role in limiting axonal growth in the adult central nervous system. Blocking these inhibitors may promote neurological recovery from spinal cord contusion. METHODS: The soluble Nogo-66 receptor (NgR(310)ecto-Fc) protein, which can neutralize three myelin inhibitors, was infused into rats after spinal cord contusion for 28 days. Treatment was initiated intrathecally at the time of injury or 3 days after injury by the intracerebroventricular route at a dose of 0.29 mg/kg/day. Recovery of locomotion and of axonal growth was assessed. Some animals received combination therapy with NgR(310)ecto-Fc plus rolipram, a cyclic adenosine monophosphate phosphodiesterase inhibitor. RESULTS: Seven weeks after spinal injury, the Basso-Beattie Bresnahan locomotor scores were significantly improved in the 3-day delayed NgR(310)ecto-Fc treatment group (9.5 +/- 0.7; n = 16) versus the vehicle-treated group, (6.75 +/- 0.7; n = 15) (p < or = 0.01, analysis of variance). The percentage of NgR(310)ecto-Fc-treated animals able to support their weight was twice that in the control group. Delayed therapy was as efficacious as acute therapy. Addition of rolipram did not alter recovery. The beneficial behavioral effects of NgR(310)ecto-Fc correlated with sprouting of raphespinal axons in the caudal spinal cord and of corticospinal axons in the rostral spinal cord. INTERPRETATION: NgR(310)ecto-Fc treatment improves outcome in a rodent model that closely mimicked human spinal cord injury.

Pubmed ID: 16958113 RIS Download

Mesh terms: Animals | Axons | Disease Models, Animal | Drug Administration Schedule | Drug Therapy, Combination | Female | Injections, Intraventricular | Locomotion | Myelin Sheath | Phosphodiesterase Inhibitors | Pyramidal Tracts | Rats | Rats, Sprague-Dawley | Recombinant Fusion Proteins | Recovery of Function | Rolipram | Spinal Cord Injuries | Time Factors | Treatment Outcome

Research resources used in this publication

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

  • Agency: NINDS NIH HHS, Id: R37 NS033020-16
  • Agency: NINDS NIH HHS, Id: R01 NS042304-09
  • Agency: NINDS NIH HHS, Id: R37 NS033020
  • Agency: NINDS NIH HHS, Id: R01 NS056485
  • Agency: NINDS NIH HHS, Id: R01 NS039962-10
  • Agency: NINDS NIH HHS, Id: R01 NS042304
  • Agency: NINDS NIH HHS, Id: R01NS39962
  • Agency: NINDS NIH HHS, Id: R01 NS056485-05
  • Agency: NINDS NIH HHS, Id: R01 NS039962

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.